乌鸦传媒

Data support that ICI rechallenge should be discouraged in patients with advanced RCC

News, features, and commentary about cancer-related issues

Similar outcomes with immediate versus delayed surgery, supporting use of active surveillance

Pembrolizumab leads to improved OS; single-agent nivolumab fails to impact DFS

Occurs most often at non-academic and low-volume centers

HIF-2 inhibitor indicated for patients who progress after immunotherapy and anti-VEGF

Phillip Pierorazio, MD, outlines how to be a good steward of active surveillance

Potential standard of care after current therapies, but key obstacles remain in the way

Building on recent success requires intervention at multiple steps in the cancer immunity cycle

A quarter of patients responded whether at the recommended or higher dose

Responses to "special drug" zanzalintinib in cabozantinib-exposed and unexposed patients

After immunotherapy-TKI failure, belzutifan produces better outcomes versus everolimus

Phase II study shows 100% local control and cancer-specific survival after more than 3 years

However, the drug did show benefit in a subgroup at highest risk of recurrence after nephrectomy